文章：

精准医疗时代下的神经母细胞瘤：临床综述

Neuroblastoma in the Era of Precision Medicine: A Clinical Review

原文发布日期：26 September 2023

DOI: 10.3390/cancers15194722

类型: Article

开放获取: 是

英文摘要：

The latest advances in treatment for patients with neuroblastoma are constantly being incorporated into clinical trials and clinical practice standards, resulting in incremental improvements in the survival of patients over time. Survivors of high-risk neuroblastoma (HRNBL), however, continue to develop treatment-related late effects. Additionally, for the majority of the nearly 50% of patients with HRNBL who experience relapse, no curative therapy currently exists. As technologies in diagnostic and molecular profiling techniques rapidly advance, so does the discovery of potential treatment targets. Here, we discuss the current clinical landscape of therapies for neuroblastoma in the era of precision medicine.

摘要翻译： 

神经母细胞瘤患者的最新治疗进展正不断融入临床试验与临床实践标准，使得患者生存率随时间推移逐步提升。然而，高危神经母细胞瘤幸存者仍持续面临治疗相关的远期后遗症。此外，对于近半数高危神经母细胞瘤复发患者而言，目前仍缺乏有效的根治性疗法。随着诊断与分子谱分析技术的快速发展，潜在治疗靶点的发现也在加速推进。本文旨在探讨精准医疗时代下神经母细胞瘤治疗的当前临床格局。

原文链接：

Neuroblastoma in the Era of Precision Medicine: A Clinical Review